Treatment

Brexanolone (Zulresso) for Postpartum Depression Cleared by the DEA, Now Available

Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression.  At that time, we were told that Zulresso would be available in June 2019. [...]

By |2020-01-05T14:34:41-04:00July 11th, 2019|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Brexanolone (Zulresso) for Postpartum Depression Cleared by the DEA, Now Available

A Primer on Brexanolone (Zulresso) for Postpartum Depression

Since the the Food and Drug Administration (FDA) approved brexanolone as an intravenous infusion for the treatment of postpartum depression last week, we have been deluged with questions from patents, providers and the media regarding [...]

By |2019-03-28T04:09:07-04:00March 28th, 2019|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on A Primer on Brexanolone (Zulresso) for Postpartum Depression

FDA is Expected to Approve Brexanolone for the Treatment of Postpartum Depression

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors.  Since that time, Sage Therapeutics [...]

By |2019-03-18T22:49:26-04:00March 18th, 2019|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on FDA is Expected to Approve Brexanolone for the Treatment of Postpartum Depression

Oral Allopregnanolone Analogue for Postpartum Depression Treatment

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD).  SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of [...]

By |2019-01-13T15:57:09-04:00January 14th, 2019|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Oral Allopregnanolone Analogue for Postpartum Depression Treatment

FDA Supports Intravenous Brexanolone for Postpartum Depression

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors.  Since that time, Sage Therapeutics [...]

By |2018-11-10T10:02:56-04:00November 10th, 2018|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on FDA Supports Intravenous Brexanolone for Postpartum Depression

Is Acupuncture Effective for Postpartum Depression?

In a recent meta-analysis, researchers screened electronic databases and analyzed data from randomized controlled trials (RCTs) of acupuncture for the treatment of postpartum depression (PPD). Primary outcomes included improvement in depressive symptoms, as by scores [...]

By |2018-11-08T11:00:14-04:00October 22nd, 2018|Alternative & Complementary, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Is Acupuncture Effective for Postpartum Depression?

Brexanolone for Postpartum Depression: More Data, But Still Some Questions

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors.  We saw the preliminary [...]

By |2018-11-08T11:05:46-04:00September 26th, 2018|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Brexanolone for Postpartum Depression: More Data, But Still Some Questions

Options for treatment of bipolar disorder during pregnancy – ObGynNews

August 23, 2018 from ObGynNews The management of bipolar disorder during pregnancy is a critical clinical situation demanding great attention to issues such as reproductive safety of psychiatric medications used by women with bipolar disorder [...]

By |2021-11-22T12:12:47-04:00September 26th, 2018|Bipolar Disorder, ObGyn News, Psychiatric Disorders During Pregnancy, Treatment|Comments Off on Options for treatment of bipolar disorder during pregnancy – ObGynNews

Brexanolone: A New Drug for Postpartum Depression

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors.  This drug was initially [...]

By |2018-06-15T11:29:21-04:00June 11th, 2018|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Brexanolone: A New Drug for Postpartum Depression
Go to Top